Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.
NCT ID: NCT03714308
Last Updated: 2023-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
554 participants
OBSERVATIONAL
2019-01-28
2023-05-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients
NCT03382587
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
NCT05473715
Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye
NCT04423718
Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye
NCT02581891
Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor
NCT01896284
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with nAMD_Treatment-naive (anti-VEGF naive)
Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
Ivt. Aflibercept (Eylea, BAY86-5321)
Treatment is applied according to routine clinical practice and independent of the study setting.
Patients with nAMD_Pre-treated with IVT-AFL
Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
Ivt. Aflibercept (Eylea, BAY86-5321)
Treatment is applied according to routine clinical practice and independent of the study setting.
Patients with nAMD_Pre-treated with any anti-VEGF
Observational period of therapy with intravitreal aflibercept (IVT-AFL) up to a maximum of 24 months
Ivt. Aflibercept (Eylea, BAY86-5321)
Treatment is applied according to routine clinical practice and independent of the study setting.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ivt. Aflibercept (Eylea, BAY86-5321)
Treatment is applied according to routine clinical practice and independent of the study setting.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Decision to initiate treatment with intravitreal aflibercept was made as per investigator's routine treatment practice or current treatment with IVT-AFL (all prior anti-VEGF treatments must have been applied by the participating study site)
* No participation in an investigational program with interventions outside of routine clinical practice
* No contra-indications according to the local marketing authorization/ Summary of Product Characteristics (SmPC)
* Ability and willingness to participate in telephone interviews
Exclusion Criteria
* Concomitant therapy (except nutritional supplements) with any other agent to treat nAMD in the study eye
* Any prior transpupillary thermotherapy, photodynamic therapy, macular rotation/ translocation or macular laser in the study eye or
* Structural damage to the center of the macula in either eye
* Any other condition expected to permanently limit visual acuity outcomes over the course of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Many locations
Multiple Locations, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19756
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.